 Supernus Pharmaceuticals Inc NASDAQ: SUPN has agreed to acquire Adamas Pharmaceuticals Inc NASDAQ: ADMS for 9.10 per share, or 450 million. The deal consideration includes 8.10 per share in cash 400 million and two non-tradable contingent value rights CVR collectively worth up to 1.00 per share in cash. 